Alivus Life Sciences Ltd (ALIVUS) is currently trading at 1,407.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Alivus Life Sciences develops and manufactures selected, high-value, non-commoditised active pharmaceutical ingredients, with emphasis on chronic therapies, generic APIs and an expanding CDMO platform. It operates manufacturing facilities in Gujarat and Maharashtra, serves regulated and emerging markets globally, and supports its portfolio through regulatory filings, process development and specialized R&D infrastructure. Q2 FY27 showed strong operating leverage: revenue rose 16.0% year over year to ₹6,820 million, while EBITDA increased 47.0% to ₹2,851 million. EBITDA margin reached 41.8%, supported by favorable product mix and operating efficiencies, indicating that earnings growth substantially outpaced sales growth during the quarter. The business is becoming less dependent on Glenmark Pharmaceuticals: non-GPL revenue grew 20.8% year over year and represented 79% of Q2 revenue. By contrast, GPL revenue contributed 21% and grew only marginally, suggesting that independent customer development and geographic diversification are increasingly important to Alivus Life Sciences. Alivus Life Sciences generated ₹2,702 million of free cash flow in Q2 and held ₹10,116 million in cash and short-term investments at September 30, 2026. This liquidity provides internal funding capacity for the company’s ongoing Solapur, Ankleshwar, Dahej and Taloja expansion programs. The development pipeline is broadening beyond conventional generic APIs. Alivus Life Sciences is advancing 30 high-potency API products, iron-complex products, oncology capabilities, flow chemistry and particle engineering, while its CDMO business grew 79.9% year over year in Q2, albeit from a relatively small base.

Over the past 52 weeks, Alivus Life Sciences Ltd has traded between a low of ₹830.00 and a high of ₹1,495.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Alivus Life Sciences Ltd has a market capitalization of approximately 17,160.38. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Alivus Life Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 25.62 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 17,160.38 Cr, Alivus Life Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Alivus Life Sciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Alivus Life Sciences Ltd is 25.62. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Revenue from operations was ₹682.0 crore in Q2 FY27, up 16.0% year-on-year from ₹590 crore.

Revenue from operations rose 6.4% YoY to ₹640.41 crore and standalone PAT rose 31.8% YoY to ₹160.08 crore.

Standalone revenue from operations was ₹640.41 crore and PAT was ₹160.08 crore in Q1 FY27.

Revenue from operations was ₹5,879.80 million and net profit (PAT) was ₹1,300.26 million in Q2FY26.